Global IVIg Liquid Market Size By Type (50ml, 25ml), By Application (Immunodeficiency, Autoimmune Disease), By Region, And Segment Forecasts, 2023 to 2032

The Global IVIg Liquid Market was valued at USD 8.1 billion in 2023 and is projected to reach USD 13.6 billion by 2031, growing at a CAGR of 6.7% during the forecast period from 2023 to 2031. Intravenous Immunoglobulin (IVIg) liquid is a critical blood product used in treating various autoimmune, infectious, and idiopathic diseases. The increasing prevalence of immunodeficiency disorders, advancements in plasma fractionation technologies, and the growing aging population are major factors fueling market growth. In addition, the rise in diagnostic awareness and expansion of plasma collection facilities globally is expected to further stimulate demand for IVIg liquid therapies.

Drivers

1. Rising Prevalence of Immunodeficiency and Autoimmune Disorders:

IVIg liquid is a standard treatment for primary immunodeficiency diseases (PIDs) and a wide range of autoimmune conditions such as Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), and myasthenia gravis. Increasing patient numbers and improved diagnostics are accelerating market demand.

2. Growth in Geriatric Population:

The elderly population is more susceptible to immunological and neurological conditions. With a growing global aging demographic, demand for immunoglobulin therapies is rising sharply.

3. Expanding Use in Off-label Indications:

Although IVIg is approved for specific conditions, its use in off-label indications is increasing. Clinicians are leveraging its immunomodulatory effects in various emerging applications, broadening its therapeutic reach.

Restraints

1. High Treatment Cost and Reimbursement Limitations:

IVIg therapy is costly due to the complexity of production and the volume of plasma required. This can limit access in price-sensitive markets, particularly where reimbursement frameworks are weak or absent.

2. Limited Plasma Supply:

A major challenge is the constrained supply of human plasma, as IVIg is derived from pooled donor plasma. Seasonal shortages and donor dependency can restrict availability and impact pricing.

Opportunity

1. Expansion of Plasma Collection Networks:

Leading pharmaceutical players and blood banks are investing in expanding plasma collection centers and enhancing fractionation capabilities, particularly in emerging markets, to address supply-demand imbalances.

2. Technological Advancements in Purification and Formulation:

Innovations in purification technologies and formulation improvements (e.g., higher concentration, lower infusion volumes) are enhancing patient convenience and safety, opening new market opportunities.

3. Rising Healthcare Access in Emerging Economies:

Growing healthcare infrastructure, government spending, and awareness campaigns in regions like Asia-Pacific and Latin America are boosting diagnosis and treatment rates for immunodeficiency conditions.

Market by System Type Insights

Based on formulation system type, the 10% IVIg Liquid concentration segment held the largest share in 2023. It is preferred due to lower infusion times and reduced patient discomfort compared to lower concentration formulations. The 5% segment is still used widely in pediatric cases or when slower administration is required, but the 10% solution continues to dominate clinical settings for its efficiency.

Market by End-use Insights

The hospital segment was the leading end-user in 2023, accounting for the highest revenue share. Hospitals represent the primary centers for IVIg infusions due to the need for trained staff and monitoring during administration. Meanwhile, the home infusion therapy segment is projected to grow rapidly, driven by cost benefits, convenience, and advances in portable infusion devices.

Market by Regional Insights

North America dominated the global IVIg Liquid market in 2023, primarily due to high diagnosis rates, advanced healthcare infrastructure, and a robust reimbursement environment in the U.S. and Canada. Europe followed closely with strong demand across Germany, France, and the UK. Asia-Pacific is expected to be the fastest-growing region, with rapid expansion of plasma collection capabilities, improving access, and increasing prevalence of chronic immune disorders in China and India.

Competitive Scenario

Key players in the Global IVIg Liquid Market include:

Grifols S.A.

CSL Behring

Octapharma AG

Kedrion S.p.A.

Bio Products Laboratory Ltd. (BPL)

Takeda Pharmaceutical Company Limited

ADMA Biologics

China Biologic Products Holdings, Inc.

Bharat Serums and Vaccines Ltd.

These companies are focused on strategic expansions, capacity upgrades in plasma fractionation, and R&D for next-generation immunoglobulin formulations. Noteworthy developments include:

2023: CSL Behring announced expansion of its U.S. plasma collection network by 15 new centers.

2024: Grifols initiated development of subcutaneous immunoglobulin (SCIg) therapies aimed at reducing hospital dependency.

2025: Takeda received regulatory approval in Japan for a new 10% IVIg liquid formulation with improved safety profile.

Scope of Work – Global IVIg Liquid Market

Key Market Developments

CSL Behring (2023) expanded its plasma sourcing capabilities in the U.S. and Europe.

Octapharma (2024) launched clinical trials for expanded indications in neurological disorders.

Grifols (2025) introduced a patient self-infusion program to accelerate adoption in home care.

FAQs

1) What is the current market size of the Global IVIg Liquid Market?

The market was valued at USD 8.1 billion in 2023.

2) What is the major growth driver of the Global IVIg Liquid Market?

The major growth driver is the rising prevalence of immunodeficiency and autoimmune disorders globally.

3) Which is the largest region during the forecast period in the Global IVIg Liquid Market?

North America is projected to remain the largest regional market due to strong healthcare infrastructure and reimbursement systems.

4) Which segment accounted for the largest market share in the Global IVIg Liquid Market?

The 10% IVIg liquid concentration segment accounted for the largest market share in 2023.

5) Who are the key market players in the Global IVIg Liquid Market?

Key players include CSL Behring, Grifols S.A., Takeda Pharmaceutical, Octapharma, and Kedrion S.p.A.